Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-fluoroadenine** is a fluorinated adenine antimetabolite and purine nucleoside analog. It is cytotoxic and has been studied mainly as a research tool for cancer and gene therapy applications. It acts by interfering with nucleic acid synthesis, leading to inhibition of cell growth and induction of cell death. In research, it has been used to select cells or organisms deficient in adenine phosphoribosyltransferase (APT) by exploiting its toxicity to wild-type cells. It can be used in the synthesis of heat shock protein 90 (Hsp90) inhibitors with anticancer activity, acts broadly as an antineoplastic agent, and has also been investigated for suicide gene therapy in human malignancy. Its cytotoxicity is notable in human leukemia cells, with an IC50 of 0.15 µM[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-fluoroadenine.